Crucell: Press Releases

ABOUT US

PRODUCT PIPELINE

TECHNOLOGY

PARTNERS

INVESTORS

NEWS

CAREERS


		Corporate Profile
		Financial Information
		Corporate Governance
		Reports & Presentations
		Press Releases
		IR Calendar & Events
		Shareholder Services


	Sign up for messages to be conveniently delivered to your email whenever new company information is posted.


	Sign up here to receive Crucell's newsletter.

Dutch German

2006 \|2005 \| 2004 \| 2003 \| 2002 \| 2001 \| 2000

23 Dec 2004	Crucell Secures € 2 Million Grant for Malaria Collaboration from Dutch Ministry of Economic Affairs
22 Dec 2004	Crucell Announces Second PER.C6® License Agreement with Chiron
16 Dec 2004	CEVEC Acknowledges Crucell Claims in Patent Infringement Hearing
15 Dec 2004	Crucell Announces Milestone Achievement in Merck's PER.C6®-related investigational HIV Vaccine Program
30 Nov 2004	Crucell Candidate for Amsterdam Midkap Index on Euronext
24 Nov 2004	Crucell Announces PER.C6® Licensing Agreement with Edwards Lifesciences
19 Nov 2004	Crucell and DSM Announce PER.C6® Licensing Agreement with Micromet for Monoclonal Antibody Production
16 Nov 2004	Crucell Discovers and Validates Human Monoclonal Antibody Product that Protects Against Rabies in Collaboration with CDC and TJU
16 Nov 2004	Crucell Presents Update on Product Development Programs at Analyst Meeting
12 Nov 2004	Crucell Signs Agreement with IAVI to Develop AdVac® Vector for AIDS Vaccine Program
10 Nov 2004	Crucell to Produce West Nile Virus Vaccine for Use in Human Clinical Trials at Netherlands Vaccine Institute, Vaccine plant opened today by Her Majesty Queen Beatrix of the Netherlands
05 Nov 2004	Crucell to Webcast Analyst Day on November 16, 2004
20 Oct 2004	Crucell to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference, October 27
18 Oct 2004	Crucell and Merial Announce Commercial License Agreement for PER.C6® Technology for Foot-and-Mouth Disease Vaccines
12 Oct 2004	Crucell Reports Third Quarter 2004 Results
07 Oct 2004	Crucell Initiates Legal Proceedings Against CEVEC Over PER.C6® Patent Infringement
06 Oct 2004	Crucell Receives Two European Patents Covering its PER.C6® and AdVac® Technology
04 Oct 2004	Aviva / Delta Lloyd Acquires 5.09% Interest in Crucell
21 Sep 2004	Crucell to Present at UBS Global Life Sciences Conference, New York, September 28
14 Sep 2004	Crucell Grants IAVI Exclusive License to use AdVac® Technology for AIDS Vaccine
13 Sep 2004	Crucell Announces PER.C6® Licensing Agreement with Vaxin for Adenoviral Vaccines
08 Sep 2004	Crucell and DSM Announce PER.C6® Licensing Agreement with MorphoSys for Antibody Production
31 Aug 2004	PER.C6®-produced HIV Vaccine Progresses Towards Next Phase
30 Aug 2004	Crucell and Harvard Medical School Announce Promising Results for Novel Vaccine Technology (AdVac®)
25 Aug 2004	Crucell Announces PER.C6® Licensing Agreement with Wyeth Pharmaceuticals
20 Aug 2004	Crucell and DSM Announce PER.C6® Licensing Agreement with Synergenics and Synco Bio Partners Investments for Production of Monoclonal Antibodies
13 Aug 2004	Crucell and DSM Announce PER.C6® Licensing Agreement with GlaxoSmithKline for Monoclonal Antibody Production
09 Jul 2004	Crucell Announces Second Quarter 2004 Results
07 Jul 2004	Crucell - DSM Biologics Alliance Announces Development Milestone Achievement
06 Jul 2004	GlaxoSmithKline Renews PER.C6® License Agreement with Crucell
25 Jun 2004	Crucell Discovers Human Monoclonal Antibody that Protects Against SARS
15 Jun 2004	Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron for Monoclonal Antibody Production
10 Jun 2004	Crucell and DSM Announce PER.C6® Licensing Agreement with Merus for Production of Monoclonal Antibody Combinations
08 Jun 2004	Crucell and DSM Announce PER.C6® Licensing Agreement with PanGenetics for Monoclonal Antibody Production
03 Jun 2004	Market authorization for PER.C6®-based West Nile virus veterinary vaccine in Israel
01 Jun 2004	Crucell's PER.C6®-based vaccine protects monkeys from Ebola
28 May 2004	Crucell Announces June 3 Webcast of Annual General Meeting of Shareholders
10 May 2004	Jan Pieter Oosterveld and Domenico Valerio nominated to Crucell's Supervisory Board
14 Apr 2004	Crucell Announces First Quarter 2004 Results
30 Mar 2004	Crucell Receives NIH Support for Candidate Malaria Vaccine Development
24 Mar 2004	Aeras partners with Crucell to develop TB vaccine
16 Mar 2004	Crucell and NeoTropiX Enter PER.C6(TM) Licensing Agreement in Viral Therapy in Oncology
16 Mar 2004	ML Laboratories Renews PER.C6(TM) License Agreement with Crucell
11 Mar 2004	Crucell acquires ChromaGenics to strengthen its strategic position in protein production technology
26 Jan 2004	Crucell Announces 2003 Annual Results
26 Jan 2004	Crucell Announces Nomination of Ronald Brus as CEO
15 Jan 2004	Crucell Signs PER.C6(TM) License Agreement with Biogen Idec
13 Jan 2004	Crucell Grants Pfizer an Exclusive License on West Nile Virus Vaccine for Horses
07 Jan 2004	Aventis and Crucell Announce Strategic Agreement to Develop and Commercialize Novel Influenza Vaccines